Caris Life Sciences released interim Achieve‑1 validation data for Caris Detect, its multicancer early detection (MCED) blood test, reporting approximately 95% specificity in 1,505 undiagnosed participants and sensitivity that rose with stage: ~57% for stage I, ~70% for stage II, ~77% for stage III and ~99% for stage IV. Combined stage I–II sensitivity was ~63%. Caris said a blinded validation cohort of 865 samples remains in process and that Achieve‑2 enrollment has begun to further define sensitivity, specificity, and detection of pre‑cancerous events. The company plans a commercial launch in Q2 and highlights specificity in asymptomatic screening cohorts as key to reducing false positives in population testing. Clinical note: High specificity is critical for population screening to limit unnecessary workups; the sensitivity profile—rising with stage—is consistent with many blood‑based MCED platforms and will inform intended use and payer discussions.